What Is AOD-9604?
AOD-9604 (Advanced Obesity Drug 9604) is a synthetic peptide fragment derived from the C-terminal end of human growth hormone - specifically amino acids 176-191, with an added tyrosine residue. It was designed to isolate the fat-metabolizing properties of HGH while leaving behind the growth-promoting and diabetogenic effects.
That distinction matters. Full-length HGH drives lipolysis (fat breakdown), but it also elevates IGF-1, can impair glucose tolerance, and carries a long list of side effects. AOD-9604 was engineered to do one thing: stimulate fat metabolism. The research to date suggests it does not raise IGF-1 levels, does not affect blood sugar, and does not promote tissue or bone growth.
For researchers and clinicians looking at targeted fat loss compounds, AOD-9604 occupies a specific niche - it is not a GLP-1 agonist like [semaglutide](/compounds/semaglutide), not a growth hormone secretagogue like [tesamorelin](/compounds/tesamorelin), and not a metabolic enzyme inhibitor like [5-amino-1MQ](/compounds/5-amino-1mq). It is its own category.
Legal Status: Category 1 - Available for Compounding
AOD-9604 is currently classified as Category 1 under the FDA compounding framework. This means licensed compounding pharmacies can legally produce it, and licensed physicians can prescribe it.
This is a significant development. During the 2023-2024 FDA crackdown on compounded peptides, many compounds were moved to Category 2 (banned from compounding). AOD-9604 survived that process and remains available through legitimate clinical channels.
What this means in practice:
- •Telehealth clinics like [Defy Medical](/clinics/defy-medical) (rated 8.8/10 in our clinic directory) can prescribe AOD-9604
- •Compounding pharmacies registered with the FDA can produce it
- •You do not need to source it from grey-market research vendors if you have a prescription
- •Quality assurance is higher through clinical channels - FDA-registered pharmacy oversight vs. vendor COAs
If you are considering AOD-9604, check our [clinic directory](/clinics) first. A prescription route gives you legal protection, medical oversight, and verified purity. For more on the legal landscape, see our [2026 peptide legality guide](/blog/are-peptides-legal-2026-guide).
How AOD-9604 Works
The mechanism is relatively straightforward compared to newer weight loss compounds.
AOD-9604 mimics the way natural growth hormone regulates fat metabolism. Specifically, it:
- 1.Stimulates lipolysis - triggers the breakdown of stored triglycerides in adipose tissue, releasing fatty acids for energy use
- 2.Inhibits lipogenesis - reduces the conversion of non-fatty food components (carbohydrates) into stored body fat
- 3.Does not affect IGF-1 - unlike full HGH or secretagogues such as [tesamorelin](/compounds/tesamorelin), AOD-9604 does not elevate insulin-like growth factor 1
- 4.Does not impair glucose metabolism - early research showed no negative effects on blood sugar regulation
The peptide interacts with beta-3 adrenergic receptors on fat cells, which is the same pathway activated during exercise-induced fat burning. It does not suppress appetite, alter satiety signaling, or affect GLP-1 pathways. The fat loss mechanism is purely metabolic - it changes how the body processes stored fat, not how much you eat.
This is both a strength and a limitation. AOD-9604 does not produce the dramatic appetite suppression that makes [semaglutide](/compounds/semaglutide) and [tirzepatide](/compounds/tirzepatide) so effective for weight loss. But it also does not cause the nausea, gastroparesis risk, or muscle loss concerns associated with GLP-1 agonists.
Key Research
AOD-9604 has a longer clinical history than most research peptides. It was originally developed by Metabolic Pharmaceuticals in Melbourne, Australia, and went through formal clinical trials - something most peptides in the research vendor market never achieve.
Preclinical Studies
Animal studies in obese mice (the ob/ob model) showed that AOD-9604 reduced body weight without affecting food intake. The peptide selectively reduced adipose tissue while preserving lean mass. Crucially, it did not produce antibodies to HGH, confirming it did not mimic the full hormone.
Phase 2 Clinical Trials
Metabolic Pharmaceuticals ran Phase 2 trials in overweight and obese adults in Australia. Results showed:
- •Statistically significant fat loss in the treatment group vs. placebo over 12 weeks
- •No elevation in IGF-1 levels, confirming the peptide does not activate HGH growth pathways
- •No adverse effects on glucose tolerance - a key concern with HGH-based therapies
- •Good safety profile - side effects were comparable to placebo
The Phase 2 data was promising, but the Phase 3 program did not advance. Metabolic Pharmaceuticals eventually pivoted the compound toward osteoarthritis (oral formulation), and AOD-9604 never received FDA approval as a standalone drug. This is not unusual - the cost of Phase 3 trials for a peptide that cannot be patented in the traditional sense makes the economics difficult.
What the Research Does Not Show
To be direct: AOD-9604 does not have the weight of evidence behind it that GLP-1 agonists do. The STEP trials for [semaglutide](/compounds/semaglutide) involved thousands of patients and showed 15-17% body weight reduction. The SURMOUNT trials for [tirzepatide](/compounds/tirzepatide) showed up to 22%. AOD-9604 Phase 2 results were more modest. If dramatic weight loss is the goal, the GLP-1 data is far stronger.
Where AOD-9604 may have value is as a targeted lipolysis agent with a clean side effect profile - useful for researchers studying fat metabolism pathways or for individuals who cannot tolerate GLP-1 agonists.
AOD-9604 vs. Alternatives
How does AOD-9604 compare to other fat loss and metabolic compounds? Here is an honest breakdown.
| Compound | Mechanism | Appetite Suppression | Clinical Evidence | Side Effect Profile | Legal Status |
|---|---|---|---|---|---|
| AOD-9604 | Lipolysis / lipogenesis inhibition | None | Phase 2 (modest results) | Very mild | Category 1 (rx available) |
| [Semaglutide](/compounds/semaglutide) | GLP-1 receptor agonist | Strong | Phase 3 (15-17% weight loss) | GI effects, muscle loss risk | FDA-approved |
| [Tirzepatide](/compounds/tirzepatide) | Dual GLP-1/GIP agonist | Very strong | Phase 3 (up to 22% weight loss) | GI effects, muscle loss risk | FDA-approved |
| [Tesamorelin](/compounds/tesamorelin) | GHRH analog (raises GH/IGF-1) | Minimal | FDA-approved for lipodystrophy | IGF-1 elevation | Category 1 (rx available) |
| [5-Amino-1MQ](/compounds/5-amino-1mq) | NNMT enzyme inhibitor | Indirect (metabolic) | Preclinical only | Limited human data | Category 2 (research only) |
The honest take: If you want maximum weight loss and can tolerate the side effects, GLP-1 agonists ([semaglutide](/compounds/semaglutide) or [tirzepatide](/compounds/tirzepatide)) have far more clinical evidence. AOD-9604 is better positioned as a milder, targeted option - particularly for individuals seeking fat metabolism support without appetite alteration, or for those who have had adverse reactions to GLP-1 therapies.
[Tesamorelin](/compounds/tesamorelin) is another growth hormone pathway compound, but it works upstream - stimulating your own GH production, which raises IGF-1. AOD-9604 works downstream on fat cells directly, without the IGF-1 elevation. Different tools for different goals.
Research Vendor Pricing
For researchers who need AOD-9604 outside of a clinical setting, here is what the current vendor market looks like. Prices are for lyophilized powder, sorted by cost efficiency.
| Vendor | Price | Vial Size | Price per mg |
|---|---|---|---|
| [Particle Peptides](/vendors/particle-peptides) | $37.99 | 5 mg | $7.60/mg |
| [Paradigm Peptides](/vendors/paradigm-peptides) | $39.99 | 5 mg | $8.00/mg |
| [Peptide Crafters](/vendors/peptide-crafters) | $80.00 | 10 mg | $8.00/mg |
| [Core Peptides](/vendors/core-peptides) | $41.00 | 5 mg | $8.20/mg |
| [Biotech Peptides](/vendors/biotech-peptides) | $44.00 | 5 mg | $8.80/mg |
| [Simple Peptide](/vendors/simple-peptide) | $45.00 | 5 mg | $9.00/mg |
| [Astro Peptides](/vendors/astro-peptides) | $45.00 | 5 mg | $9.00/mg |
| [Peptide Sciences](/vendors/peptide-sciences) | $65.00 | 6 mg | $10.83/mg |
The price spread is relatively tight. Particle Peptides and Paradigm Peptides offer the best per-mg value at $7.60-8.00/mg. The Peptide Crafters 10 mg vial is worth noting - at $8.00/mg, the larger vial size may be more convenient for longer research protocols.
A reminder: since AOD-9604 is Category 1, you can also obtain it through a [licensed clinic](/clinics) with a prescription. The per-unit cost may be higher through a clinic, but you get pharmaceutical-grade product with medical supervision.
For full vendor scoring methodology, see [how we score vendors](/methodology). Browse all options on our [vendor rankings page](/vendors).
The Bottom Line
AOD-9604 is a well-characterized peptide with a specific, narrow use case: stimulating fat metabolism without the baggage of full growth hormone therapy. It has real clinical trial data behind it - more than most research peptides - but that data is modest compared to the blockbuster GLP-1 results.
Who should consider AOD-9604:
- •Researchers studying fat metabolism pathways independent of appetite regulation
- •Individuals who cannot tolerate GLP-1 agonists and need an alternative approach
- •Those who want a compound with a clean safety profile and no IGF-1 elevation
Who should look elsewhere:
- •Anyone seeking significant weight loss - GLP-1 agonists like [semaglutide](/compounds/semaglutide) and [tirzepatide](/compounds/tirzepatide) have dramatically stronger evidence
- •Researchers focused on growth hormone pathways - [tesamorelin](/compounds/tesamorelin) is more relevant
- •Those with no medical guidance - talk to a clinician, especially since AOD-9604 is legally available through [telehealth clinics](/clinics)
The best thing about AOD-9604 right now is its legal status. As a Category 1 compound, you do not need to navigate the grey market. A licensed physician can prescribe it, and an FDA-registered pharmacy can compound it. That alone makes it worth discussing with a provider rather than sourcing independently.
For more on the peptide compound page, see [AOD-9604 compound data](/compounds/aod-9604).